International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Epratuzumab (Primary) ; Asparaginase; Asparaginase; Crisantaspase; Crisantaspase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Prednisolone; Tioguanine; Vincristine; Vindesine
- Indications Acute lymphoblastic leukaemia
- Focus Registrational; Therapeutic Use
- 03 May 2017 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
- 25 Aug 2015 Planned End Date changed from 1 Sep 2019 to 1 Apr 2021 as reported by ClinicalTrials.gov.
- 25 Aug 2015 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2021 as reported by ClinicalTrials.gov.